NCT03319953 - A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

September 11, 2019

Study Completion Date

November 6, 2019

Conditions

Stable Schizophrenia

Interventions

DRUG

TAK-041

TAK-041 suspension

DRUG

Placebo

TAK-041 placebo-matching suspension

DRUG

Second Generation Antipsychotics (SGA)

Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Trial Locations (1)

Kings College London, London